The antisickling agent, 5‐hydroxymethyl‐2‐furfural: Other potential pharmacological applications

Abstract

For the last two decades, the aromatic aldehyde 5‐hydroxymethyl‐furfural (5‐HMF) has been the subject of several investigations for its pharmacologic potential. In 2004, the Safo group reported that 5‐HMF has potent antisickling activity by targeting and ameliorating the primary pathophysiology of hypoxia‐induced sickling of erythrocytes (red blood cells [RBC]). Following the encouraging outcome of the preclinical and phase I/II clinical studies of 5‐HMF for the treatment of sickle cell disease (SCD), there have been multiple studies suggesting 5‐HMF has several other biological or pharmacologic activities, including anti‐allergic, antioxidant, anti‐hypoxic, anti‐ischemic, cognitive improvement, anti‐tyrosinase, anti‐proliferation, cytoprotective, and anti‐inflammatory activities. The wide range of its effects makes 5‐HMF a potential candidate for treating a variety of diseases including cognitive disorders, gout, allergic disorders, anemia, hypoxia, cancers, ischemia, hemorrhagic shock, liver fibrosis, and oxidative injury. Several of these therapeutic claims are currently under investigation and, while promising, vary in terms of the strength of their evidence. This review presents the research regarding the therapeutic potential of 5‐HMF in addition to its sources, physicochemical properties, safety, absorption, distribution, metabolism, and excretion (ADME) profiles.